The clinical significance of serum S-lOO protein, a protein released by damaged brain tissue, was assessed in patients with acute ischaemic or haemorrhagic stroke and matched controls. Serum S-100 protein concentration was significantly elevated in patients with ischaemic stroke [median (SQR): 0·27 (0'09) J-lg/L, n = 68] and haemorrhagic stroke [0-43 (0'23) J-lg/L, n = 13] compared to controls [0,11 (0'03)J-lg/L, n=51, P<O·OOOI]. Although patients with haemorrhagic stroke had higher serum S-100 concentrations compared to patients with ischaemic stroke, this was not quite statistically significant. Serum S-100 concentrations were related to infarct size, large (total anterior circulation) infarcts concentrations having the highest [0-40 (0'22) Jlg/L], and small vessel ('lacunar') infarcts concentrations having the lowest [0,20 (0'06) Jlg/L, P<0·0005] concentrations. S-100 protein concentration was also significantly related to clinical outcome at three months measured using three disability and handicap scales (n = 81): modified Barthel index (r, = -0·285, P=O'OI), modified Rankin score (r,=0'313, P=0'004) and Lindley score (r,=0'262, P=0'018) with high values associated with poor clinical outcome. Similarly high values of serum S-100 protein were observed in patients who died or were discharged to an institution [median (SQR): 0·63 (0'29) J-lg/L and 0·37 (0'13) Jlg/L, respectively] compared to those who were discharged home [0,26 (O·ll)J-lg/L, P=0·13]. The present study suggests measurement of serum S-100 protein could be a useful prognostic marker of clinical outcome in acute stroke. Whether 8-100 concentrations can be altered by therapeutic intervention in acute stroke remains to be elucidated. Indexing terms: acute stroke/serum S-100/Barthe1 index/Rankin scale.
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Protein 8-100 is an acidic calcium-binding protein with a molecular weight of 21 kDa, first purified from bovine brain. I Although it is found in a wide variety of vertebrates with very little structural variation, its biological function is largely unknown. The protein consists of two subunits IX and p, which are combined to give IXIX (S-100ao), IXP (8-100a) and PP (S-100b) heterodimeric forms. It is present in tissues of different origin, including various cells of the nervous system, adipocytes and melanocytes (8-100a and b) and in striated muscle, heart and kidney (8-100ao ).2-3 In the brain, 8-100 is much more Correspondence: Ms Hagosa D Abraha. 366 abundant than in other tissues and is present as a mixture ofS-100b and S-lOOa; S-100b concentrations are 3Q-lOO-fold higher than S-100a. 4 S-100 is present in and secreted from both normal and transformed glial cells.> Structural damage to the glial cells causes leakage of S-I 00 protein into the extracellular compartment and then into cerebrospinal fluid (CSF), eventually entering the bloodstream.r"
Previous studies have suggested that the S-100 protein concentration in CSF could be a useful marker for assessing the extent of brain damage in patients with cerebral lesions. 6 • 9 -1O Unlike CSF S-100, serum S-100 measurement is noninvasive and therefore can be measured sequentially during follow-up of patients. Only one study has previously examined serum S-IOO protein in neurological disease in any detail." This group used a particle counting immunoassay of S-100 in serum, with a detection limit of 0·31lg/L, in 325 patients with various neurological diseases. They found serum S-100 concentrations below the limit of detection in all cases of multiple sclerosis, dementia and meningitis. A few of their patients with peripheral neuropathy, meningoradiculitis, encephalitis and Guillain-Barre syndrome had initially raised serum S-IOO. Significant elevations were seen in patients with tumours of the central nervous system (meningioma, glioblastoma and neurinoma) and in 43 patients with cerebrovascular disease. However, they did not attempt to relate the serum S-100 results to lesion type or size, or to clinical outcome in their patients.
The aim of this study was to determine whether the concentration of serum S-IOO protein is altered in patients with acute stroke and to correlate its concentration with the type and size of brain lesion as well as with the clinical outcome.
SUBJECTS AND METHODS
Venous blood samples were collected for protein S-IOO assay within 48 h of stroke onset in 81 patients admitted to the Acute Stroke Unit at King's College Hospital, II between May 1994 and August 1995. Serial samples were taken at 24, 48, 72 and 96 h in 13 of these patients. Blood samples were centrifuged at 1500g for 10 min within 4 h of venepuncture and serum stored at -20°C until the time of analysis. In all patients the diagnosis and classification of stroke was made on clinical grounds and the type of lesion (infarction versus haemorrhage) confirmed using computed tomography (CT) neuroimaging (Siemens Somatom DRH) within 3 days of stroke onset. Measurement of serum S-IOO was carried out without knowledge of the patient's status. Discharge destination or death was noted for all patients. Blood samples were taken at three months post-stroke in 57 of 74 (77%) surviving patients. The study was approved by the King's Healthcare Research Ethics Committee.
The clinical outcome of the patients at 3 months were assessed using functional outcome measures of disability, the Barthel index, 12 handicap, the Rankin scale," and the dependence/independence score of Lindley" in all patients. The Barthel and Rankin measures were Serum S-lOO protein and stroke 367 modified to include all causes of mortality, death equalling -1 and 6, respectively. All outcome measures were performed 'blinded' to the admission S-100 results and by the same person to prevent inter-observer variation. The reference group consisted of 51 age, gender and race matched subjects, who were free from any previous history of neurological disease or other : chronic illness, recruited from the population of a local primary care practice.
Serum S-100 was measured by an immunoradiometric assay (IRMA Sangtec, Bromma, Sweden). Whilst originally developed for assay of S-100 in CSF the assay has been validated and used by ourselves and others with serum samples. The Sangtec 100 kit measures the 'a' and 'b' isoforms of protein S-lOO and requires 1001lL of serum. The assay was modified to give a lower standard of O'31lg/L by diluting the higher standard (601lg/L) with the diluent provided with the kit. The limit of detection was 0·051lg/L based on the point where the intraassay imprecision exceeds a coefficient of variation (CV) of 10%. Intra-assay CV were 2·8% at 0'181lg/L (n = 10), O' 7% at 1·51lg/L (n = 10) and 0·8% at 5'31lg/L (n = 10) and inter-assay CV were 3·3%, 4·4% and 1'5%, respectively.
Statistical analysis
Data are reported as median and semi-quartile range (SQR), since the serum S-100 results were not normally distributed. Statistical differences between the groups were analysed using the Robust Rank Order Test and Kruskal-Wallis one-way ANOVA by ranks for unpaired comparisons, the Wilcoxon signed ranks test and Friedman two-way ANOVA by ranks for paired comparisons, and the X 2 test for frequency data.'" Spearman's rank order correlation coefficient (r,) was used for assessing associations. Values of P<0·05 were accepted as statistically significant.
RESULTS
No significant difference was observed with respect to age, gender or race for the 68 patients with ischaemic stroke, 13 with primary intracerebral haemorrhage and the 51 normal controls (Table 1 ). In both infarct and haemorrhage groups the median serum S-100 protein concentration was significantly higher than in the control group. Patients with cerebral haemorrhage had higher serum S-IOO levels than those with ischaemic stroke (Fig. 1) although, infarcts (LACI) and posterior circulation infarcts (POCI). Serum S-100 level was related to infarct size, the highest levels were observed with the largest infarcts (TACI) and the lowest levels with the small vessel (lacunar) infarcts ( Table 2) .
A comparison of serum S-l 00 concentration on admission and 3 months post stroke was carried out in 57 (77%) of the 74 surviving patients. Serum S-100 at 3 months was significantly lower, median (SQR) = 0·19 (0'04) 1lg/L compared to its concentration on admission 0·27 (0'11) 1lg/L, P<O·OOOI (Fig. 2) .
In the combined group of patients with strokes (infarct and haemorrhage), serum S-IOO concentration was related to clinical outcome (disability, handicap and death) at 3 months following the onset of stroke using the modified Barthel index (MBI), Rankin score (MRS) and Lindley score. There was a significant correlation between S-100 concentration and the clinical outcome of the patients: MBI The clinical classification developed by the Oxfordshire Community Stroke Project" was used as a surrogate measure of stroke lesion size: large; total anterior circulation infarcts (TACI), medium; partial anterior circulation infarcts (PACI), small; deep white matter small lacunar (r,= -0'285, P=O'OIO), MRS (r,=0'313, P= 0,004) and Lindley score (r, = 0,262, P = 0,018). Hence, high serum 5-100 concentration at the time of admission reflected poor outcome at 3 months.
Although, higher serum S-100 concentrations were observed in those samples taken on admission in patients who subsequently died [0'63 (0'29) Ilg/Lj or were discharged to an institution ['poor outcome', O' 37 (0'13) Jlg/Lj compared with those who were discharged home ['good outcome', 0·26 (0'11) Ilg/Lj, this difference did not reach significance (Kruskal-Wallis one-way ANOYA by ranks, H=4·15, P=0·13).
DISCUSSION
Stroke is a major cause of death and the most common cause of chronic disability in adults in developed countries. Although there is currently no effective drug treatment for acute stroke.!? it remains important to find ways of predicting outcome so that rehabilitation resources can be directed at those patients who will benefit most. Current, but imprecise predictors of stroke outcome include assessment of lesion volume using CT or magnetic resonance imaging, and the presence of certain clinical features such as age, coma and incontinence. It is therefore desirable to have a biochemical marker which might improve the prediction of clinical outcome in patients with acute stroke. Based on C5F measurements neurone specific enolase and S-100 protein have emerged as potential candidate compounds for such a role."
Prospective studies have shown a relationship between C5F 5-100 protein concentration and the degree of brain damage in patients with various neurological disorders including ischaemic stroke, intra-cerebral haemorrhage, subarachnoid haemorrhage, multiple sclerosis, acute encephalomyelitis and head injury.6,18,20 Although an elevated 5-100 protein concentration is not specific for stroke, this is of little consequence as the differential diagnosis of these conditions is based on clinical findings and imaging techniques.
Astroglial cells are the most common cells in brain tissue. It has been proposed that astroglial cell death caused by the entrance of Ca + + , follows brain ischaemia.P Leakage of 5-100 protein into the circulation may therefore reflect damage to astroglial cells. This is supported by the present data which showed significant elevation of serum 5-100 in both the infarct and intra-cerebral haemorrhage groups compared to a control group. Furthermore, serum 5-100 concentrations were highest in stroke patients with large total anterior circulation infarcts and lowest in patients with small lacunar infarcts. Thus, serum 5-100 appears to reflect the extent of brain damage in stroke patients. This finding extends the work of Fagnart et at. 7 who first measured serum 5-100 protein using particle counting immunoassay in patients with cerebrovascular disorders (n = 48). He reported that more than 90% of the patients had serum S-100 greater than O' 3 Jlg/L and this agrees with the result of C5F 5-100 measurements reported by Aurell et a/. 20 To investigate temporal changes in the disease process, serum 5-100 was measured consecutively in 13 patients during the first 96 h. Although 5-100 concentrations were elevated, no dramatic changes were observed during this period. This is consistent with other studies which have shown peak concentration of 5-100 in C5F and serum between 48 hand 7 days after brain injury.6,20 The long lasting peak after stroke means that 5-100 can be measured at any time during the first few days after stroke, an important attribute in any prospective prognostic test.
In 57 of the surviving patients the concentration of serum S-100 on admission and at three months post-ictus was evaluated. A significant fall in serum 5-100 concentration was observed at 3 months compared to the samples taken on admission. This possibly indicates the partial recovery of astroglial integrity.
In this study the clinical outcome of the patients was assessed using the modified Barthel index, modified Rankin scale, Lindley score, and discharge destination or death. The significant correlation of serum S-IOO concentration and clinical outcome measured by three of the four different methods 3 months later supports its potential use as an additional predictive marker of clinical outcome. Although Aurell et al. 20 demonstrated a relationship between the peak concentration of CSF S-IOO, glial fibrillary acidic protein and the clinical state of the patient at the time of sampling, no previous studies have attempted to determine if this also applied to the long-term outcome of patients.
Although serum S-IOO protein may reflect the extent of a lesion, clinical outcome is dependent not only on the extent of the brain damage but also on its site as well as other factors such as rehabilitation. In this respect, assessment of serum S-IOO protein may provide useful information for evaluating the effect of treatment to reduce brain damage.
